Lung Cancer Clinical Trial

A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer

Summary

This Phase 2 study evaluates HBI-8000, a histone deacetylase inhibitor (HDACi) in combination with pembrolizumab for the treatment of patients with advanced or metastatic non-small cell lung cancer who possess programmed death ligand 1 (PD-L1) expression Tumor Proportion Score (TPS) of 1% or greater.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histopathologically confirmed diagnosis of NSCLC with PD-L1 expression of ≥1% based on FDA-approved test
No prior treatment with checkpoint inhibitors or more than one regimen of chemotherapy including epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation directed therapy for advanced or metastatic disease
Disease must have at least 1 measurable target lesion by RECIST 1.1
Adequate major organ functions as evidenced by laboratory findings within 14 days prior to first dose
Eastern Cooperative Oncology Group (ECOG) ≤2 and must have a life expectancy of ≥12 weeks

Exclusion Criteria:

History of grade ≥3 hypersensitivity reactions to monoclonal antibodies
Participation in another interventional clinical trial within 28 days or less than 5 half-lives of investigational agent before the first dose
Recurrent pleural effusion requiring repetitive palliative thoracentesis within 3 months prior to study entry (except patients with a PleurX™ port)
Active, known or suspected autoimmune disease or history of immune-mediated toxicity leading to discontinuation of previous checkpoint inhibitor treatment should be administered in (neo)adjuvant setting. Exceptions are for type I diabetes mellitus, hyperthyroidism requiring hormone-replacement or skin only disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic therapy
Active pneumonitis, history of non-infectious pneumonitis that required treatment with steroids, or history of interstitial lung disease
Received approved live vaccines within 30 days of planned first dose. Intranasal influenza vaccines (e.g. Flu-Mist) are not allowed, however inactivated viral vaccines or vaccines based on subviral component are allowed
Any condition requiring chronic systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications. And any steroids use within 14 days of first dose except for inhaled or topical steroids.

Note: Other protocol-defined Inclusion/Exclusion criteria may apply

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

24

Study ID:

NCT05141357

Recruitment Status:

Recruiting

Sponsor:

HUYABIO International, LLC.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

Western Regional Medical Center
Goodyear Arizona, 85338, United States
CBCC Global Research, Inc at Comprehensive Blood and Cancer Center
Bakersfield California, 93309, United States
Hematology Oncology Associates Of The Treasure Coast
Port Saint Lucie Florida, 34952, United States
Southeastern Regional Medical Center
Newnan Georgia, 30265, United States
Midewestern Regional Medical Center, LLC
Zion Illinois, 60099, United States
Cotton O'Neil Clinical Research Center
Topeka Kansas, 66606, United States
Frederick Health-JMSCI
Frederick Maryland, 21702, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

24

Study ID:

NCT05141357

Recruitment Status:

Recruiting

Sponsor:


HUYABIO International, LLC.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.